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The objective of this study is to establish the efficacy
of adherence therapy (AT) compared with treatment
as usual (TAU) in reducing blood pressure (BP) in non-
compliant hypertensive patients. This study was designed
as a parallel-group single-blind randomised controlled
trial. The study was carried out at three general hospital
outpatient clinics in Jordan. A total of 136 non-compliant
hypertensive patients with a mean baseline BP of
164.5mmHg (s.d. 10.0) over 102.2mmHg (s.d. 7.0)
participated in the study. 7 weekly 20-min sessions of
AT in addition to TAU. The main outcome of this study is
systolic blood pressure (SBP) at 11-weeks follow-up. In
all, 68 patients received TAU and 68 AT. Intention-to-treat
analysis included all participants randomised. AT lowered
SBP by  23.11mmHg (95% CI:  25.85,  20.36) and
diastolic BP (DBP) by  15.18mmHg (95% CI:  17.55,
 12.80) at 11 weeks compared with TAU. Adherence
(measured by pill counting) was also improved in the AT
group by 37% at 11 weeks compared with TAU. No
significant adverse events were reported. AT increases
adherence to medication for hypertension which then
leads to a clinically important reduction in BP.
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Introduction
Hypertension is defined as a blood pressure (BP)
(systolic/diastolic) X140/90mmHg.
1 Hypertension
is one of the major cardiovascular diseases world-
wide; in 2000 26% of the adult population had
hypertension.
2 Hypertension has been estimated to
be responsible for 4% of the global burden of
disease, that is, 64 million disability adjusted life
years.
3 In both developing and developed regions it
is a major cause of morbidity and mortality,
particularly cardiovascular and renal diseases.
Reductions in BP are associated with reductions
in the incidence of stroke and cardiovascular heart
disease.
4,5 However, systolic blood pressure (SBP)
has the stronger association (compared with diasto-
lic blood pressure (DBP)) with the global disease
burden attributable to hypertension.
4,6,7 The risk of
cardiovascular disease and stroke rises continuously
as SBP increases above 115mmHg.
8,9
Worldwide successful control of hypertension is
poor with only 5–58% of people taking antihyper-
tensive medications managing to achieve a BP of
less than 140/90mmHg.
10 One of the major factors
in this poor control is lack of patient adherence to
treatment.
11 Adherence behaviours are complex,
ranging from completely ceasing to take prescribed
medications, to taking only some, to taking them in a
way that differs from instructions for example, not
after food. Overall hypertensive patients are esti-
mated to take only 53–70% of the medication
prescribed for them.
12–14 Factors that affect adher-
ence are complex but may include beliefs about
illness and treatment, side effects and complexity of
treatment regimes.
1,15,16
The National Institute for Health and Clinical
Excellence
17 and the WHO
1 in their respective
guideline and review strongly advocate the adoption
of an individualised consultation style that recog-
nises the importance of involving patients in
treatment decisions as key to enabling clinicians to
enhancing adherence. A focus on exploring patients’
beliefs about illness and treatment and providing
specific information about the disease (hyperten-
sion) and its treatments (medication and life-style
modification) are also strongly advocated for exam-
ple, by using face-to-face education sessions or
information leaflets. This guidance is based largely
on observational research and to date there has been
little experimental evidence to establish the clinical
benefit of such a consultation style. Reviews of
adherence interventions in general
18 and in hyper-
tension specifically
19 have reported that much of the
experimental work to date has generally taken a
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reminders and self monitoring) approach to enhan-
cing adherence; most have been shown to be
ineffective.
The intervention under investigation in this trial,
adherence therapy (AT), is rooted in the observation
that patient’ beliefs impact on their treatment
adherence.
20 For example, patients who do not
believe that their health depends on medicines,
worry about having to take medicine or are con-
cerned about the side effects of medicine are less
likely to adhere to treatment than patients with more
positive treatment attitudes for example, ‘my med-
icines protect me from becoming more sick’.
21
AT was developed from work with non-adherent
patients with mental health problems and was
described initially as compliance therapy.
22 It is a
patient-centred approach normally delivered by
trained clinicians over a series of 7 weekly 20-min
consultations each with a different theme. Building
on a structured adherence assessment key therapy
techniques include, generating discrepancy; medi-
cation problem solving; exchanging information;
exploring ambivalence; and checking beliefs. Theo-
retically, these techniques amplify the personally
relevant benefits of treatment, modify illness and
treatment beliefs and resolve ambivalence towards
taking medication.
Considering two of the AT techniques, generating
discrepancy and checking beliefs, in more detail.
The therapist can amplify the personally relevant
benefits of medication by generating discrepancy
between what the patients says is important to them
(for example, being able to work, not visiting
hospital so frequently, not worrying family) and
what they actually do that is, not taking medication.
The therapist might respond to a patient who says
that their medication is important but repeatedly
misses doses by saying: ‘Im a bit confused, because
you say that you need to keep your blood pressure
under control so that you are able to work and yet
you keep missing doses of medication, can you help
me understand that a bit better?’.
Beliefs identified from the assessment that may
negatively affect adherence are explored using a
three-step process. Step 1, the patient is asked to
rate the conviction (as a percentage), with which
they hold a belief (for example, the patient says they
are 60% sure most medication is addictive). Step 2,
they are then asked to generate evidence that
supports and refutes the belief. Step 3, the therapist
rechecks the conviction, with which the belief is
held. This process provides patients an opportunity
to ‘test out’ their beliefs. Direct confrontation or
challenge of the belief is avoided.
Each consultation follows a standard structure
(review of previous meeting and homework, set
agenda, task (for example, exploring ambivalence),
feedback and setting homework). A copy of the AT
manual is available from the authors on request.
The concept that we are seeking to test in this trial
is that AT will modify patient’s unhelpful beliefs
about taking their medication, which will in turn
improve compliance, which will result in a reduc-
tion in patients’ BP.
Our randomised controlled trial will therefore test
the following hypotheses:
1. AT leads to a reduction in BP in people with
hypertension at 11 weeks, compared with treat-
ment as usual (TAU).
2. AT modifies patient’s attitudes and beliefs in a
favourable direction towards taking their medica-
tion compared with TAU, as measured by the
Beliefs about Medications Questionnaire.
3. AT improves adherence to antihypertensive med-
ication compared with TAU.
Methods
A parallel-group randomised controlled trial of
adherence therapy. AT was compared with TAU.
The assessors of BP and adherence and the data
analyst were blinded to the group assignment.
Study participants
All hypertensive patients that met our selection
criteria who attended the outpatient clinics in three
government run hospitals, which serve 70% of the
Jordanian population, were invited to participate.
The trial was conducted between August 2009 and
January 2010. Jordan has a population of over
6 million people, of whom it is estimated that 26%
are hypertensive.
23 Treatment non-adherence in this
population is estimated to be 57%.
24
Eligible patients were adults (X18 years) with a
diagnosis of hypertension, currently hypertensive
that is, BP X140/90mmHg (information extracted
from case notes), and on monthly follow-up sche-
dules at the participating clinics. Records were
selected for assessment on the basis that the patients
had been seen recently in the clinics. Records were
assessed in reverse date order of last clinic appoint-
ment, and assessment of potential participants was
stopped when sufficient numbers had been re-
cruited to the study. Potential participants were
screened with the Morisky Medication Adherence
Scale
25 (MMAS) before the trial. Those assessed as
non-adherent were invited to participate. Patients
were excluded if they had:
(a) complications of hypertension, had diabetes,
congestive heart failure and renal impairment.
These patients were excluded because their
treatment regime was more likely to be com-
plex, introducing more potential confounders
that might not be adequately dealt with by
randomisation.
(b) mental illness or any other long-term health
conditions for example, asthma, Parkinson’s
disease, epilepsy, cancer and chronic obstructive
pulmonary disease. These patients were ex-
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also introduce confounding factors that might
limit the effectiveness of the therapy
(c) pregnant patients were excluded as the aetiology
and duration of their hypertension would likely
differ from essential hypertension.
We identified 181 eligible non-adherent patients,
45 of whom refused to participate, the remaining
136 agreed to participate in the study and provided
written informed consent.
Ethical approval
Appropriate permissions and ethical approvals were
given by the Ministry of Health in Jordan and the
University of East Anglia’s ethics committee.
Sample size
We expected to observe a difference of 3mmHg in
SBP between the groups.
26,27 Assuming a s.d. of 5.7,
(see refs 28, 29) an alpha of 0.05, a 2-tailed test of
significance, and 80% power, we required 60
patients in each arm of the trial, that is, a sample
size of 120. We estimated from previous studies of
adherence interventions in hypertensives
30 that at
most 12% (that is, 16) of patients would withdraw
from the study, so we aimed to recruit 136 patients.
Randomisation
FA checked patient eligibility and consent against a
checklist. FA was allocated a personal 6-digit ‘PIN’
identifier that allowed her access to the online
independent randomisation service at the Clinical
Research Trials Unit (CRTU) at the University of
East Anglia (UEA). On entry of a valid PIN, the
system generated a unique Study Code and ran-
domly allocate the patients to either the AT or TAU
arm of the trial. The study code and allocation was
sent in an email to FA and the trial database
manager and stored in the trial database on the
secure CRTU server at UEA.
A computer generated randomisation list allo-
cated the 136 patients in a 1:1 ratio to ATor TAU. To
ensure a reasonably even distribution of patients in
the two arms throughout the course of the trial,
patients were allocated in randomly permuted
blocks of four and six.
Intervention
Control group: patients received TAU, which con-
sisted of monthly outpatient clinics where BP was
measured, medication reviewed and laboratory
investigations and other care was delivered depend-
ing on individual needs. We did not provide any
guidelines about what constituted usual care. TAU
was provided by the patients usual clinical care
team. This consisted of a clinician-led team of
medical and nursing staff based in the outpatient
clinic.
Experimental group: In addition to TAU, patients
in the experimental group received seven one-to-one
sessions of AT lasting 20min over a 7-weeks period.
AT was delivered by FA who received one-to-one
training in AT over seven sessions each lasting 1h
from RG who developed the intervention. AT
sessions were delivered in the hospital outpatient
clinics (B25% of all sessions) or at the patient’s
home (B75% of all sessions) depending on patient
preference. Treatment fidelity was checked by an
independent rater (AHN) against an AT scale using
audio tapes of a random selection of sessions.
Translations
The translations to Arabic language for AT, Morisky
Medication Adherence Scale (MMAS) and Beliefs
about Medicines Questionnaire (BMQ,) was based
on The Eight Steps Translation Process that com-
bined the recommendations of WHO
31 and Brislin
et al.
32–34
Demographical information and patient characteristics
We recorded the following demographical informa-
tion and patient charcateristics at the baseline
assessment: age, gender, living arrangements, mar-
ital status, smoking status, self-reported levels of
physical activity, self-reported adherence to a low-
salt, low-fat diet, employment status, presence of
medical insurance and levels of education. These
were assessed using a questionnaire developed by
the study’s authors.
Outcomes
The primary outcome, for this study, was the
difference in SBP from baseline to follow-up (11
weeks after randomisation). If the results of this
study are positive, subsequent trials should then test
the durability of the intervention. Our secondary
measures were the difference in DBP, medication
adherence rates and BMQ from baseline to follow-
up (11 weeks after randomisation). BP was mea-
sured by a nurse blinded to the group allocation and
time of intervention at baseline and 11 weeks. The
BP was measured using a stethoscope with mercury
sphygmomanometer twice from the right upper arm
of a seated patient who had been resting for more
than 10min. The average of the two measurements
was used. Patients were asked to not smoke or drink
coffee during the examination and it was recorded if
they had any alcohol, coffee or cigarettes in the
30min before the examination.
35,36
At 11 weeks, percentage adherence was calculated
by dividing the number of pills not taken in the
preceding month by the total number prescribed.
Pill counting was carried out by a nurse blinded to
group allocation.
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and beliefs toward medication.
21 We considered
using the specific version of the BMQ, which
relates to patients attitudes to a single medi-
cation but as hypertension patients tend to be
prescribed multiple drugs, we considered the
general version of the measure to be more appro-
priate. Each item is rated on a five-point Likert-
type scale ranging from ‘strongly disagree’ (1) to
‘strongly agree’ (5). The BMQ has established
validity and is routinely used as an outcome
measure in adherence research. The question-
naire has four sections that evaluate attitudes
about:
1. General harm (G-H) that is, the intrinsically
harmful properties of medications (four questions
such as ‘most medicines are addictive’).
2. General overuse (G-O) of medications by health-
care professionals (four questions such as ‘Doc-
tors use too many medicines’).
3. General sensitivity (G-S) to adverse events from
medications (five questions such as ‘my body is
very sensitive to medicines’).
4. General benefit (G-B) that is, the intrinsically
beneficial properties of medications (four ques-
tions such as ‘in most cases the benefit of
medicines outweigh the risks’).
Finally a note was made of the amount of time
taken to deliver the AT, so that an estimate of the
costs of delivery could be made.
Data analysis
The data analyst (AC) was blinded to group allo-
cation. All analyses were conducted on an inten-
tion to treat basis. Although there was very little
missing data (six patients died, three discontinued
AT and one lost to follow-up, Figure 1) this was
dealt with by multiple imputation of missing
data being based on iterative chain equation model-
ling including all available outcome measures
and their baseline values and treatment arm. Five
imputed data sets were created, which were then
analysed and combined using Rubin’s equations.
37
The differences in change of BP and BMQ were
assessed using an unadjusted analysis and after
adjusting for possible prognostic factors (gender,
education, economic status and medical insurance
status) using an analysis of covariance. Adherence
rate and medication change were similarly analysed
using logistic regression with only treatment arm
as a covariate, as an unadjusted analysis and
an adjusted analysis was based on included prog-
nostic factors. Subgroup analyses of change in
SBP by the use or not of cardiovascular medi-
cation and the use of two or more antihyperten-
sive drugs or not at baseline was based on testing
for an interaction effect in a regression model
at baseline.
Results
We recruited 136 non-adherent patients with hyper-
tension and randomised them equally to the AT and
TAU groups. Six patients (three in each group) died
before the end of the study, three withdrew from the
ATintervention and one patient in the AT group was
lost to follow-up (see participant flow diagram).
Tables 1 and 2 show the demographical and clinical
characteristics of participants in the trial.
Table 3 summarizes the change from baseline in
BP, adherence and beliefs for both groups. The
results show that SBP is reduced in the AT group by
23.4 (95% CI: 20.7, 26.2) mmHg more than in the
TAU group and similarly, DBP is reduced in the AT
group by 15.6 (95% CI: 13.2, 17.9) mmHg more than
in the TAU group. Because of the imbalance
between treatment groups at baseline in terms of
gender, economic status, education and medical
insurance, an analysis was conducted adjusting for
these factors and the baseline value of the outcome.
The adjusted and unadjusted analyses produced
very similar results.
The BMQ scores show that beliefs about medications
in the AT group also move away from a view that
medications are intrinsically harmful (G-H  5.7)
and towards one that recognises the benefits of the
medications (G-B 2.7) with little or no change in
attitudes over the period of the study in the TAU group.
The patients in this study were taking an average
of 2.6 antihypertensive medications and a further
0.7 other medications daily. There was no signifi-
cant difference in the numbers of patients who
changed their hypertensive medications during the
11-week period of the study (AT: 12%, TAU: 25%).
Patients in the AT group took substantially more
of their medications (97%) compared with those in
the TAU group (71%). There was no significant
difference in the average adherence rate between
individuals on monotherapy compared with those
prescribed two or more antihypertensive medica-
tions in either the AT or TAU groups.
Our proposed mechanism of action is that ATwill
positively influence attitudes and beliefs about
medications, which will improve adherence, and
which will, in turn, reduce BP. The BMQ scores
indicating negative beliefs about medication were
all negatively correlated with adherence (GH:  0.73,
Po0.001, G-O:  0.31, Po0.001 and G-S:  0.46,
Po0.001) and the BMQ General Benefit score was
positively correlated with adherence (0.44,
Po0.001), that is a reduction in negative beliefs
and an increase in positive beliefs about medication-
improved adherence. The adherence scores were
negatively correlated with BP (SBP:  0.71,
Po0.001, DBP:  0.63, Po0.001) that is, an improve-
ment in adherence reduced BP. Finally, we also
identified that the BMQ scores indicating negative
beliefs were positively correlated with SBP (G-H:
0.75, Po0.001; G-O: 0.20, P¼0.028; G-S: 0.53,
Po0.001) and the BMQ General Benefit score was
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that is, negative beliefs about medication are
associated with higher SBP and positive beliefs
about medication are associated with lower SBP.
We estimated the cost of the delivery of the
intervention was seven-AT sessions 20min that
is, 2h 20min of a mid-grade nurse (mid-Band six in
the United Kingdom, including all employer’s costs)
plus the hire of a suitable room in an outpatient
clinic for the same duration. From this we calcu-
lated that the price of a course of AT would be
approximately US$ 130 per person.
Discussion
Current clinical guidelines
17,38 on strategies for
enhancing adherence are based largely on observa-
tional data that has yet to be tested in a robust RCT.
AT incorporates all of the key elements of the NICE
and WHO guidelines,
17,38 and this study represents a
rigorous test of them.
Size of effect
We were surprised by the size of effect of the
AT on adherence (37% increase) and BP (SBP
 23.1mmHg. (95% CI:  25.85,  20.36), DBP
 15.2mmHg (95% CI:  17.55,  12.80)). Although
the sample size of 136 patients was modest the
confidence intervals for the effect are narrow due to
the small variation in BP in this population. A
previous Cochrane systematic review of RCTs of
adherence therapies in hypertension
19 had demon-
strated up to a 41% increase in adherence, and
reductions of up to 19.5mmHg in SBP, and
* All analyses conducted on an intention to treat basis with multiple imputation of missing
data.
6028 Patient records available at clinics
1230 Patients records available for those
who had recently attended clinics
351 Patient records assessed for eligibility in
reverse date order of attending clinics.
Recruitment stopped when sufficient
numbers of participants recruited
251 Excluded
45 refused to participate
136 Randomised
68 started TAU 68 started AT
3 died
3 discontinued AT
1 lost to follow up
3 died
65 completed follow-up
68 analysed*
61 completed follow up
68 analysed*
170 did not meet inclusion criteria i.e.
137 diabetic, 10 congestive heart
failure, 7 kidney impairment, 3
mentally ill, 4 cerebrovascular
accident, 9 pregnant
Figure 1 Participant Flow Diagram. *All analyses conducted on an intention to treat basis with multiple imputation of missing data.
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was short (4 weeks) so the impact of the AT was
maximised and may not have suffered from decay in
effect that might be expected with a longer follow-
up period.
Changes in BP compared with previous
pharmacological studies
Law’s review
39 of 354 RCTs of BP-lowering drugs
showed that the average BP of trial participants was
154/97mmHg (90% range: SBP 139–170, DBP 97–
106), making our patient’s baseline average BP (164/
102mmHg) towards the top of the range that is
usually recruited into hypertension trials. They
determined that patients placed on two drugs had
an average reduction of 14.6mmHg for SBP and
8.6mmHg for DBP. Our patients were prescribed
2–3 antihypertensive drugs on average, which may in
part account for the larger reductions in BP observed
(SBP 23.1mmHg, DBP 15.2mmHg). It may also
be that patients recruited to pharmaceutical trials
tend to be selected for adherent behaviours; conse-
quently there may be less potential room for
improvement (the ceiling effect). The patients in
our study were specifically selected for their non-
adherence to their medication at baseline, and as
compliance levels improved so dramatically in the
AT group, we may be observing close to the
maximum change capable of being achieved by
these antihypertensive drugs.
Causal mechanism
The hypertensive patients all began the study with
relatively neutral beliefs about medication, but poor
adherence behaviours. Those in the AT group
shifted their opinions so that overall they disagreed
with statements regarding the intrinsically harmful
nature of medicines, and overall agreed with
statements regarding the intrinsically beneficial
nature of medicines. This shift in beliefs led to a
change in adherence behaviour (37% improvement
in the number of pills taken over 1 month), which
Table 1 Baseline demographical characteristics of participants
Characteristics AT Group
n¼68 n (%)
TAU Group
n¼68 n (%)
Age (mean, s.d.) 53.4 (10.7) 53.9 (11.7)
Female 43 (63) 30 (44)
Living alone 4 (6) 9 (13)
Marital status: Married 56 (82) 47 (69)
Marital status: Single/widower 12 (18) 21 (31)
Current smoker 19 (28) 25 (37)
Currently exercising
a 22 (32) 20 (29)
Keeping restricted diet
b 30 (44) 23 (34)
Working 33 (49) 42 (62)
Not working 35 (51) 26 (38)
Medically insured 29 (43) 36 (53)
Medically uninsured 39 (57) 32 (47)
Education: None 2 (3) 10 (15)
Education: Educated 66 (97) 58 (84)
Abbreviations: AT, adherence therapy; TAU, treatment as usual.
aMinimum exercise of walking 30min per day,
bAdhering to low-salt, low-fat diet.
Table 2 Baseline clinical characteristics of participants
Characteristics AT Group
n¼68
Mean (s.d.)
TAU Group
n¼68
Mean (s.d.)
Systolic blood pressure 165.6 (10.1) 163.4 (9.7)
Diastolic blood pressure 103.2 (7.0) 101.3 (6.9)
Number of antihypertensives
prescribed daily
2.7 (0.8) 2.4 (0.6)
Number of other medications
prescribed daily
0.9 (1.0) 0.5 (0.8)
BMQ: General harm 13.5 (2.4) 12.4 (3.0)
BMQ: General overuse 15.4 (2.3) 14.9 (2.0)
BMQ: Sensitivity to drugs 14.9 (2.7) 15.0 (2.1)
BMQ: General benefit 13.6 (2.4) 14.3 (2.3)
Table 3 Analysis of outcome measures (change from baseline)
Outcome AT TAU Unadjusted Adjusted
N Mean (s.d.) N Mean (s.d.) Mean difference
(95% CI)
P-value Mean difference
(95% CI)
P-value
SBP 68  22.1 (9.7) 68 1.0 (5.5)  23.1 ( 25.9,  20.4) o0.01  21.6 ( 24.4,  18.8) o0.01
DBP 68  14.7 (8.6) 68 0.5 (3.9)  15.2 ( 17.6, -12.8) o0.01  12.8 ( 15.0,  10.6) o0.01
G-H 68  5.8 (2.4%) 68  0.1 (1.1)  5.67 ( 6.3,  5.0) o0.01  5.0 ( 5.6,  4.4) o0.01
G-O 68  1.2 (1.9) 68 0.1 (1.3)  1.3 ( 1.9,  0.8) o0.01  1.4 ( 2.1,  0.8) o0.01
G-S 68  1.8 (1.6) 68 0.02 (1.32)  1.8 ( 2.3,  1.3) o0.01  1.9 ( 2.4,  1.4) o0.01
G-B 68 2.6 (2.4) 68 0.37 (1.59) 2.3 (1.5, 3.0) o0.01 1.8 (1.2, 2.5) o0.01
Percentage adherence
at 11 weeks
68 97.2% (4.0) 68 70.6% (10.7) 26.7% (23.9, 29.4) o0.01 26.4% (23.4, 29.4) o0.01
Medication changes
over 11 weeks
68 8.2 (12.1%) 68 16.8 (24.7%) OR (95% CI)
0.4 (0.2, 0.6)
0.08 OR (95% CI)
0.6 (0.2, 1.7)
0.30
Abbreviations: AT, adherence therapy; DBP, diastolic blood pressure; G-H, general harm; G-O, general overuse; G-S, general sensitivity;
G-B, general benefit; OR, odds ratio; SBP, systolic blood pressure; TAU, treatment as usual.
Unadjusted analysis based on a two-sample t-test and adjusted analysis based on an analysis of covariance model.
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target ranges (Mean SBP/DBP 143/88mmHg). No
such shift in medication beliefs or adherence
behaviours was observed in the TAU group, and
their endpoint BP had barely changed from baseline
(Mean SBP/DBP 164/102mmHg). That we have
been able to demonstrate how our AT has impacted
on BP is important and particularly pleasing
because few, if any, previous adherence studies
have been able to establish this. To an extent this
observation also counters one of the major weak-
nesses of our trial; a lack of a control intervention
that addresses the non-specific effects of the
therapy.
Adjustments to prescriptions
In our study there was no significant difference in
the rates of prescribing adjustments in either group,
although the TAU group did change their medica-
tion more often. Our study had a short period of
follow-up (1 month) which may have reduced the
likelihood of us detecting differences in the rates of
medication adjustment between the two groups.
Ogedegbe
40 reported that the effect of motivational
interviewing intervention led to steady maintenance
of adherence in hypertensive African Americans,
over 12 months follow-up compared with a
significant reduction in adherence noted in the
usual care group. This effect was also associated
with greater frequency of adjustments in medication
in the usual care group. Thus with a longer follow-
up period we may have observed similar changes.
One factor that is known to reduce adherence is to
take more than one drug. Currently, it is recom-
mended that two anti-hypertensive medications
should be prescribed for most people with hyperten-
sion in order to maximize BP control.
41 However,
our results showed no association between the
number of prescribed drugs and the rate of adher-
ence in either group.
Cultural issues
To our knowledge this is the first RCT that has tested
the effect of AT on reduction in BP and medication
adherence among mainly Muslim hypertensive
patients. Griffiths
42 has suggested that a belief in
the predetermination (‘takdir’ or destiny) of the
Islamic life-course can present a barrier to the
uptake of interventions that aim to improve health
behaviours. The success of our intervention refutes
this, although we acknowledge that Islamic beliefs
and behaviours vary across the world and the fact
that FA is from Jordan meant that she undoubtedly
presented the AT in a culturally acceptable manner.
Global impact of hypertension
Hypertension was estimated to be present in 26%
of the adult population in 2000, which represents
972 million patients. The number of adults with
hypertension in 2025 is predicted to increase by
about 60% to a total of 1 56 billion.
2 It has been
estimated that the cost of hypertension was US$ 370
billion globally in 2001, and indirect costs could be
as high as US$ 3600 billion annually. This repre-
sents about 10% of the world’s overall healthcare
expenditure.
43
Although a formal evaluation of cost effectiveness
could not be conducted with the data collected from
this study, we calculated that the price of a course of
AT would be approximately US$ 130 per person.
Observational studies have predicted that a long-
term reduction of 10mmHg DBP would be predicted
to lead to at least a 56% reduction in stroke and a
37% reduction in chronic heart disease.
5 Our study
showed a short-term reduction of 15.2mmHg DBP,
which even if the size of this effect were attenuated
somewhat over time, and considering the substan-
tial costs outlined above and the sizeable preventive
effect for serious sequelae of reductions in DBP, it
would seem reasonable to suggest that this inter-
vention is likely to be cost effective.
Strengths and weaknesses of the study
Our process of randomisation was only partially
successful in balancing the baseline characteristics
of the two groups as there were differences in terms
of gender balance, employment status, education
levels and medical insurance status. Although the
use of a single therapist limits the generalisability of
this intervention, we believe that this was mitigated
as FA was trained according to the standard manual
to deliver AT and the fidelity of her delivery was
confirmed. This model of AT has also been used
successfully to increase adherence in other long
term conditions—for example, schizophrenia.
44
Patients were aware of the fact that they were
being monitored because this was explained to them
in the patient information sheet. This may have
encouraged them to be more adherent with treat-
ment than usual. The lack of change in BP in the
TAU group suggests that this did not occur. How-
ever, we recognise that because of the relationship
the patients in the AT group developed with FA
during therapy, they might have not wanted to let
her down, and been particularly adherent during the
assessment period. This effect may have been
enhanced by the short follow-up period (4 weeks).
We used pill counting after 1 month to estimate
the level of adherence, but we recognize that the
absence of pills does not necessarily mean that the
patient has correctly taken their medications. Pill
counting cannot identify other types of non-adher-
ence, such as inappropriate timing or dosage.
Implications for future research
All of the AT was delivered by a single person (FA)
in this study. This reduces our ability to state that
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clinicians. Future research should be conducted
with more therapists to counter the potential ‘halo’
effect of a single highly motivated nurse delivering
treatment. Future studies should also follow more
participants over a longer period to increase our
understanding of the durability of the effect in a
larger and potentially more diverse population.
Adherence to medication is complex and future
trials may wish to determine whether drug doses
were taken in the correct amount and at the correct
time. Future studies should also collect data to
enable a cost effectiveness analysis to be conducted.
An important question when applying ATin clinical
practice is whether a short-term intervention (one
session per week over 7 weeks) is sufficient to
maintain BP-lowering effect over time. Other as-
pects of AT need to be tested to determine the
robustness and generalisability of this therapy.
Aspects to be tested could include frequency and
intensity of the therapy, the location of its delivery,
the mode of delivery (for example, by telephone),
the numbers to whom it is delivered (for example,
one-to-one or group sessions), the character of the
person delivering the AT (for example, lay advisors),
and whether the duration of effect could be
enhanced by the use of top-up sessions.
Implications for practice
From our findings it can be concluded that a
relatively short dose of AT is sufficient to reduce
BP and improve adherence to medication for at least
1 month. It is possible that these results reflected
changes in patient’s behaviour, attitudes and beliefs
that would lead to regular drug intake eventually
becoming a habitual behaviour.
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